Skip to main content
Fig. 6 | Breast Cancer Research

Fig. 6

From: Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors

Fig. 6

Elacestrant exhibits anti-tumor activity and downregulates key cell cycle proteins in multiple models of CDK4/6i resistance. a Pictorial representation of elacestrant activity in multiple models of CDK4/6i resistance. b Elacestrant activity, represented as IC50 and TGI, as a single agent and in combination in multiple models of CDK4/6i resistance. c Western blot analysis of indicated cell cycle proteins in in vitro models of palbociclib resistance. d Western blot analysis of indicated cell cycle proteins from tumors harvested 4 h post-last dose in the PDX-R1 model. e Western blot analysis of indicated cell cycle proteins from tumors harvested 4 h post-last dose in the WHIM43 model. f PDX tumors were harvested 4 h post-last dose in the PDX-R1 model. FFPE tumor sections were prepared and subjected to IHC with Ki67 antibody (Code# IR626, Agilent). The percent and their staining intensity were assessed by an expert breast pathologist blinded to the treatment to generate an H-score (t test). Representative images for each IHC were shown. Magnification, × 40

Back to article page